RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and maintains $235 price target.
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.